The following government grants in the FederalGrants.com database contain the term National Institutes of Health in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
| Grant Title | CFDA | Funding Number |
| NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed) |
93.113, 93.121, 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867 |
RFA-NS-24-030 |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) |
93.213 |
PAR-24-123 |
| NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) |
93.213 |
PAR-24-115 |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) |
93.213 |
PAR-24-116 |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) |
93.213 |
PAR-24-124 |
| Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required) |
93.847 |
RFA-DK-23-011 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) |
93.855 |
PAR-24-100 |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not Allowed) |
93.279 |
RFA-DA-25-034 |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Basic Experimental Studies with Humans (BESH) Required) |
93.279 |
RFA-DA-25-033 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) |
93.855 |
PAR-24-099 |
| Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) |
93.279 |
RFA-DA-25-054 |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trial Optional) |
93.279 |
RFA-DA-25-032 |
| Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed) |
93.279 |
RFA-DA-25-053 |
| Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) |
93.855 |
RFA-AI-24-003 |
| Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) |
93.855 |
PAR-24-111 |
| Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) |
93.855 |
PAR-24-112 |
| Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) |
93.113, 93.121, 93.213, 93.233, 93.242, 93.273, 93.279, 93.313, 93.361, 93.837, 93.838, 93.839, 93.840, 93.846, 93.853, 93.866 |
RFA-NR-24-004 |
| Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed) |
93.310, 93.351 |
PAR-24-129 |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) |
93.853 |
PAR-24-098 |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) |
93.853 |
PAR-24-097 |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) |
93.853 |
PAR-24-095 |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) |
93.853 |
PAR-24-096 |
| International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed |
93.173, 93.398, 93.989 |
PAR-24-113 |
| Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network - 3 (U24 Clinical Trial RequiredInfrastructure) |
93.279, 93.310, 93.859, 93.865 |
RFA-OD-24-009 |
| Clinical Sites for the Environmental influences on Child Health Outcomes (ECHO) IDeA States Pediatric Clinical Trials Network - 3 (UG1 Clinical Trial Required) |
93.279, 93.310, 93.859, 93.865 |
RFA-OD-24-008 |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) |
93.393, 93.399 |
PAR-24-122 |
| International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) |
93.173, 93.398, 93.989 |
PAR-24-114 |
| High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) |
93.279 |
RFA-DA-25-060 |
| NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) |
93.172 |
RFA-HG-24-013 |
| Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional) |
93.172 |
PAR-24-107 |
| Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult Services (U01 Clinical Trials Optional) |
93.172 |
RFA-HG-24-001 |
| Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional) |
93.172 |
PAR-24-106 |
| Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) |
93.273, 93.279 |
PAR-24-060 |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) |
93.847 |
PAR-24-103 |
| NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) |
93.847 |
PAR-24-094 |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) |
93.847 |
PAR-24-102 |
| Limited Competition: Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed) |
93.351 |
PAR-24-105 |
| NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) |
93.279 |
PAR-24-089 |
| NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) |
93.172 |
RFA-HG-24-006 |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) |
93.853 |
PAR-24-101 |
Search Results 161-200 of 14606
[Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 [Next] |
